Funding for this research was provided by:
This article is maintained by: Elsevier
Article Title: Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Journal Title: Pulmonology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/J.PULMOE.2020.08.007
Content Type: simple-article
Copyright: © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U.